VolitionRx Ltd., a multi-national epigenetics company, has provided a consolidated update highlighting recent clinical and commercial progress across its key diagnostic platforms. The company submitted a manuscript for peer review showcasing both a new method called Capture-Seq and new biomarkers for cancer detection, estimating this represents an annualized total addressable market opportunity of approximately $23 billion.
Commercialization of the company’s Nu.Q Cancer assay progressed specifically in lung cancer, with reimbursement submission in France reported as on track. Routine clinical use of the assay is expected by the fourth quarter of 2026. Volition also confirmed inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France for early detection of sepsis, highlighting the assay’s CE-marked availability across European markets.
New clinical utility data was presented for the company’s assay in Hidradenitis Suppurativa, a chronic inflammatory skin condition. In veterinary medicine, breakthrough results demonstrated 100% specificity in detecting feline lymphoma using the Nu.Q Vet Feline assay. Publication of the feline study is expected to unlock a $5 million contractual milestone payment for the company.
Volition confirmed ongoing licensing discussions with approximately 10 global diagnostic leaders and stated it anticipates announcing additional licensing agreements during 2026. The company’s research and development activities are centered in Belgium, with additional facilities in the United States and London. For further information, visit the company’s website at https://www.Volition.com.
The company’s progress spans multiple disease areas and represents significant steps toward making epigenetics-based blood tests more accessible for early disease detection and monitoring. These developments have implications for improving patient outcomes through earlier intervention across both human and veterinary medicine.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VolitionRx Reports Clinical and Commercial Progress Across Cancer Detection and Sepsis Monitoring Platforms.